Discovery of an irreversible HCV NS5B polymerase inhibitor

Zeng, Q., Nair, A. G., Rosenblum, S. B., Huang, H-C., Lesburg, C. A., Jiang, Y., Selyutin, O., Chan, T-Y., Bennett, F., Chen, K. X., Venkatraman, S., Sannigrahi, M., Velazquez, F., Duca, J. S., Gavalas, S., Huang, Y., Pu, H., Wang, L., Pinto, P., ... Kozlowski, J. A. (2013). Discovery of an irreversible HCV NS5B polymerase inhibitor. Bioorganic and Medicinal Chemistry Letters, 23(24), 6585-6587. https://doi.org/10.1016/j.bmcl.2013.10.060

Abstract

The discovery of lead compound 2e was described. Its covalent binding to HCV NS5B polymerase enzyme was investigated by X-ray analysis. The results of distribution, metabolism and pharmacokinetics were reported. Compound 2e was demonstrated to be potent (replicon GT-1b EC50 = 0.003 mu M), highly selective, and safe in in vitro and in vivo assays. (C) 2013 Elsevier Ltd. All rights reserved.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Community overdose surveillance
Article

Epigenetic biomarkers for smoking cessation
Article

A pilot PT scheme for external assessment of laboratory performance in testing synthetic opioid compounds in urine, plasma, and whole blood